TABLE 4.

Adjusted overall survival estimates for patients undergoing resection by receipt of neoadjuvant therapy and cancer site; ampullary adenocarcinoma

Variable	HR (95% CI)	p
Neoadjuvant therapy (ref. = upfront resection)
Yes	0.96 (0.69–1.33)	0.783
Patient age (ref. = age < 45 years)
45–65 years	1.65 (1.03–2.65)	0.038
>65 years	2.53 (1.58–4.06)	<0.001
Gender (ref. = male)
Female	0.78 (0.71–0.87)	<0.001
Race (ref. = white)
Black	1.07 (0.88–1.31)	0.5
Other	0.94 (0.78–1.14)	0.549
Insurance (ref. = no)
Insured	1 (0.73–1.36)	0.981
Comorbidity score (ref. = 0)
Comorbidity score 1	1.21 (1.08–1.36)	0.001
Comorbidity score ≥ 2	1.29 (1.07–1.56)	0.007
Hospital type (ref. = community)
Academic	1.02 (0.76–1.37)	0.911
Comprehensive community	1.12 (0.83–1.5)	0.475
Clinical tumor stage (ref. = stage I)
Stage II	1.59 (1.43–1.76)	<0.001
Neoadjuvant radiation (ref. = no)
Yes	0.99 (0.52–1.91)	0.985
Adjuvant chemotherapy (ref. = no)
Yes	0.89 (0.8–0.99)	0.036

HR hazard ratio, CI confidence interval, p p-value, ref. reference